Par's reported, or GAAP, loss from continuing operations for the year ended , included the write-off of an intangible asset zithromax ampule and certain inventories related to the trimming of its generic product portfolio amoxicillin and potassium clavulanate of $5.5 million, a charge related antibiotics
to a can i use triple antibiotic ointment on a yeast infection government pricing contingency of $4.8 million, a $7.8 million net impairment charge related to various investments, $7.5 million in development milestone payments to MonoSol Rx and Alfacell, and $9.0 million of gains from the sale of non-core ANDAs amoxicillin best absorb be taken with food and other product rights. Par Pharmaceutical Reports Fourth Quarter and Full Year 2008 Results WOODCLIFF LAKE, N.J., / - / -- Par Pharmaceutical antibiotic Companies, Inc.
For the fourth quarter ended , Par reported total revenues of clopidogrel bisulfate
- $161.3 million and a loss from continuing operations of $30.5 review antibiotics online million, or $0.91 per share. For the year ended , Par reported total revenues of $578.1 million and a loss from continuing operations of $45.9 million, or $1.38 per share. This is compared with reported revenues of $769.7 million and income from continuing operations of $51.1 million, or $1.47 per diluted share, for 2007. Adjusting for these items and other special items, income amoxycillin from amoxicillin antibiotic omega 3 use continuing operations for the fourth quarter 2008 would have been $7.1 million, or $0.21 per diluted share. By comparison, fourth quarter can azithromycin turn strep black 2007 results included a pre-tax gain of $3.1 million from Par's sale of its remaining investment in Optimer Pharmaceutical, Inc.
PRX) today reported fourth quarter and full year 2008 results ended. Fourth quarter 2008 reported, or GAAP, loss from continuing operations also included the write-off of a restructuring kundenbewertungen zu meds drugstore med charge of $15.4 million and other related costs of $3.8 million, $49.2 million in charges due to an unfavorable court decision and related legal azithromycin antibiotic for acne fees, $5.3 million generic symmetrel
- gain on non-core ANDA sales amoxicillin and the sale of other product rights, $4.9 million impairment charge related to various investments, and a $7.9 herpes and triple antibiotic cream million gain related to hyman debt extinguishment.
Adjusting for these items, income from continuing operations for the fourth quarter of 2007 would have been $6.5 million, or $0.19 per diluted share. Adjusting for these items and the fourth antibiotic for gram negative rods rod quarter special items, income from continuing operations for the full year ended would have been $1.8 million, or $0.05 per diluted share. Com stock and $4.6 million of additional share-based usa online pharmacy butibal compensation expense related to Par's employee stock option tender offer. This is compared with reported revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share, for the same period in 2007. By comparison, and in addition to the fourth quarter 2007 events cited above, reported GAAP income from continuing operations for the full year 2007 included a $20.0 million gain.